Safety and Effectiveness Evaluations for Diabetes

糖尿病的安全性和有效性评估

• 批准号: 8005837
• 负责人: DONALD R MILLER
• 金额: --
• 依托单位: EDITH NOURSE ROGERS MEMORIAL VETERANS HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8005837
• 关键词: 2,4-thiazolidinedione; Acarbose; Acute Renal Failure with Renal Papillary Necrosis; Adverse event; Agonist; Aldosterone; Amputation; Benefits and Risks; Blindness; Blood Glucose; Cardiovascular Diseases; Caring; Cessation of life; Chronic Disease; Chronic Kidney Failure; Clinic; Clinical; Clinical Trials; Code; Combined Modality Therapy; Congestive Heart Failure; Consensus; Data; Data Linkages; Diabetes Mellitus; Diabetic Angiopathies; Diagnosis; Disease Progression; Effectiveness; Epidemiologic Methods; Epidemiology; Evaluation; Event; Fracture; Future; Glimepiride; Glipizide; Glucagon; Glyburide; Heart failure; Hemoglobin; Hepatotoxicity; Hyperglycemia; Hypoglycemia; Incidence; Individual; Insulin; Isophane Insulin; Kidney Diseases; Laboratories; Lactic Acidosis; Lead; Link; Longitudinal Studies; Lower Extremity; Medical; Medicare; Metformin; Methodology; Methods; Monitor; Morbidity - disease rate; Myocardial Infarction; Neuropathy; New Agents; Observational Study; Oral; Outcome; Outcome Study; Pancreatitis; Patient Monitoring; Patients; Peptides; Pharmaceutical Preparations; Pharmacy facility; Pioglitazone; Pneumonia; Policies; Population; Prevalence; Prevention; Procedures; Process; Recommendation; Records; Registries; Regression Analysis; Relative (related person); Relative Risks; Renin; Reporting; Research; Research Personnel; Resources; Retinal Diseases; Risk; Risk Estimate; Safety; Sampling; Services; Simulate; Source; Staging; Stroke; Sulfonylurea Compounds; Surveys; System; Techniques; Testing; Thiazolidinediones; Time; Treatment Protocols; Uncertainty; Variant; Veterans; Weight; Woman; Work; base; cardiovascular disorder risk; cohort; comparative; computerized data processing; cost; design; diabetes management; diabetes mellitus therapy; disability; effective therapy; efficacy trial; exenatide; experience; follow-up; glargine; glycemic control; health administration; health care service utilization; high risk; inhibitor/antagonist; macrovascular disease; men; mortality; receptor; respiratory; rosiglitazone